-
Volume 72, June 2023 - current issue
-
Vol 27, September 2019
-
Vol 26, August 2019
-
Vol 25, July 2019
-
Vol 24, June 2019
-
Vol 23, May 2019
-
Vol 22, April 2019
-
Vol 21, March 2019
-
Vol 20, February 2019
-
Vol 19, January 2019
-
Vol 18, December 2018
-
Vol 17, November 2018
-
Vol 16, October 2018
-
Vol 15, September 2018
-
Vol 14, August 2018
-
Vol 13, July 2018
-
Vol 12, June 2018
-
Vol 11, May 2018
-
Vol 10, April 2018
-
Vol 9, March 2018
-
Vol 8, February 2018
-
Vol 7, January 2018
-
Vol 6 No 12, December 2017
-
Vol 6 No 11, November 2017
-
Vol 6 No 10, October 2017
-
Vol 6 No 9, September 2017
-
Vol 6 No 8, August 2017
-
Vol 6 No 7, July 2017
-
Vol 6 No 6, June 2017
-
Vol 6 No 5, May 2017
-
Vol 6 No 4, April 2017
-
Vol 6 No 3, March 2017
-
Vol 6 No 2, February 2017
-
Vol 6 No 1, January 2017
-
Vol 5 No 12, December 2016
-
Vol 5 No 11, November 2016
-
Vol 5 No 10, October 2016
-
Vol 5 No 9, September 2016
-
Vol 5 No 8, August 2016
-
Vol 5 No 7, July 2016
-
Vol 5 No 6, June 2016
-
Vol 5 No 5, May 2016
-
Vol 5 No 4, April 2016
-
Vol 5 No 3, March 2016
-
Vol 5 No 2, February 2016
-
Vol 5 No 1, January 2016
-
Vol 4 No 12, December 2015
-
Vol 4 No 11, November 2015
-
Vol 4 No 10, October 2015
Cover Story Current Issue

Altered amino acid metabolism is increasingly appreciated as a key driver in the pathology of multiple diseases, including metabolic syndrome, cancer, and neurological disease. Sphingolipids (SLs) are synthesized from serine and fatty acyl-CoAs by serine palmitoyltransferase (SPT) and are critical signaling molecules and membrane components that are enriched in the nervous system and retina. When serine levels are low, alanine (or glycine) is used as a substrate by SPT to yield non-canonical 1-deoxysphingolipids (doxSLs) that drive neuropathy and cellular dysfunction through diverse mechanisms. This highlights a potential mechanism for crosstalk between amino acid metabolism and SL biosynthesis in the context of neurological dysfunction. Numerous heritable neurological and retinal disorders are causative or linked to mutations in genes encoding SL-metabolizing enzymes, including amyotrophic lateral sclerosis (ALS), Tay-Sachs, Niemann-Pick disease, Gaucher disease, Macular telangiectasia type II (MacTel), and hereditary sensory and autonomic neuropathy type 1 (HSAN1).
Courtney R. Green, Roberto Bonelli, Brendan R.E. Ansell, Simone Tzaridis, ... Marin L. Gantner
Current Issue
Intestinal SEC16B modulates obesity by regulating chylomicron metabolism
Objective
Genome-wide association studies (GWAS) have identified genetic variants in SEC16 homolog B (SEC16B) locus to be associated with obesity and body mass index (BMI) in various populations. SEC16B encodes a scaffold protein located at endoplasmic reticulum (ER) exit sites that is implicated to participate in the trafficking of COPII vesicles in mammalian cells. However, the function of SEC16B in vivo, especially in lipid metabolism, has not been investigated.
Methods
We generated Sec16b intestinal knockout (IKO) mice and assessed the impact of its deficiency on high-fat diet (HFD) induced obesity and lipid absorption in both male and female mice. We examined lipid absorption in vivo by acute oil challenge and fasting/HFD refeeding. Biochemical analyses and imaging studies were performed to understand the underlying mechanisms.
Results
Our results showed that Sec16b intestinal knockout (IKO) mice, especially female mice, were protected from HFD-induced obesity. Loss of Sec16b in intestine dramatically reduced postprandial serum triglyceride output upon intragastric lipid load or during overnight fasting and HFD refeeding. Further studies showed that intestinal Sec16b deficiency impaired apoB lipidation and chylomicron secretion.
Conclusions
Our studies demonstrated that intestinal SEC16B is required for dietary lipid absorption in mice. These results revealed that SEC16B plays important roles in chylomicron metabolism, which may shed light on the association between variants in SEC16B and obesity in human.
Intestinal SEC16B modulates obesity by regulating chylomicron metabolism
Objective
Genome-wide association studies (GWAS) have identified genetic variants in SEC16 homolog B (SEC16B) locus to be associated with obesity and body mass index (BMI) in various populations. SEC16B encodes a scaffold protein located at endoplasmic reticulum (ER) exit sites that is implicated to participate in the trafficking of COPII vesicles in mammalian cells. However, the function of SEC16B in vivo, especially in lipid metabolism, has not been investigated.
Methods
We generated Sec16b intestinal knockout (IKO) mice and assessed the impact of its deficiency on high-fat diet (HFD) induced obesity and lipid absorption in both male and female mice. We examined lipid absorption in vivo by acute oil challenge and fasting/HFD refeeding. Biochemical analyses and imaging studies were performed to understand the underlying mechanisms.
Results
Our results showed that Sec16b intestinal knockout (IKO) mice, especially female mice, were protected from HFD-induced obesity. Loss of Sec16b in intestine dramatically reduced postprandial serum triglyceride output upon intragastric lipid load or during overnight fasting and HFD refeeding. Further studies showed that intestinal Sec16b deficiency impaired apoB lipidation and chylomicron secretion.
Conclusions
Our studies demonstrated that intestinal SEC16B is required for dietary lipid absorption in mice. These results revealed that SEC16B plays important roles in chylomicron metabolism, which may shed light on the association between variants in SEC16B and obesity in human.
2021 impact factor: 8.568
Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.